Recordati Patents – Key Insights and Stats

Recordati has a total of 914 patents globally, out of which 518 have been granted. Of these 914 patents, more than 36% patents are active. The USA is where Recordati has filed the maximum number of patents, followed by European Countries. Parallelly, the USA seems to be the main focused R&D centre of Recordati.

Recordati was founded in the year 1926. Company is an international pharmaceutical group. As of March 2023, Recordati has a market cap of $8.74 Billion.

Do read about some of the most popular patents of Recordati which have been covered by us in this article and also you can find Recordati patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Recordati patent portfolio.

How many patents does Recordati have?

Recordati has a total of 914 patents globally. These patents belong to 166 unique patent families. Out of 914 patents, 334 patents are active.

How Many Patents did Recordati File Every Year?

Recordati Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantRecordati Applications FiledRecordati Patents Granted
202274
2021724
2020533
2019516
2018419
20171225
20162223
20153238
2014440
20133421
20122236
20113728

Which Recordati Drug Patents are Expiring in the Next 10 Years?

The patent no. US10709691B2 which is expiring in Oct, 2035, describing dosage forms for treating Cushing’s disease or Cushing’s syndrome contain the drug 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or its pharmaceutically acceptable salt.

Given below is the list of few drugs patented by Recordati accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
Isturisa US10709691B2Pharmaceutical Dosage FormsOct, 2035
Signifor Lar KitUS7759308B2Microparticles Comprising Somat…Oct, 2026
SigniforUS7473761B2Somatostatin AnaloguesDec, 2026

How many Recordati patents are Alive/Dead?

Recordati Patent Portfolio

How Many Patents did Recordati File in Different Countries?

Recordati Worldwide Patent Filing

Countries in which Recordati Filed Patents

CountryPatents
United States Of America73
Europe55
Germany48
Australia38
Spain35
China34
Denmark31
Canada30
Norway29
Poland26
Brazil25
Israel24
Hong Kong (S.A.R.)22
New Zealand21
Taiwan21
Korea (South)20
Portugal20
South Africa19
Singapore19
Japan18
Mexico17
Indonesia16
India14
Austria14
Viet Nam14
Eurasia14
Slovenia14
Malta14
Croatia10
Ukraine10

Where are Research Centres of Recordati Patents Located?

R&D Centres of Recordati

10 Best Recordati Patents

US7612182B2 is the most popular patent in the Recordati portfolio. It has received 75 citations so far from companies like Ethicon Endo-Surgery, Kodiak Sciences, and Novo Nordisk.

Below is the list of 10 most cited patents of Recordati:

Publication NumberCitation Count
US7612182B275
US20040198789A171
US7955597B262
US7473761B260
US7071197B251
US7833786B246
US8415337B141
WO2003014084A136
US20030069285A134
US20030180355A131

What are Recordati key innovation segments?

What Technologies are Covered by Recordati?

The chart below distributes patents filed by Recordati in different countries on the basis of the technology protected in patents. It also represents the markets where Recordati thinks it’s important to protect particular technology inventions.

R&D Focus: How has Recordati search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Recordati?

Related Articles

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.